Technically speaking, shares of MYL surged higher on the positive earnings report and tagged a fresh 52-week high Thursday.

FORBES: Options Watch

To take advantage of a continued rally in the shares of MYL, traders should consider the equity's July 19 call.

FORBES: Magazine Article

While the number of MYL shares sold short dropped by 25% during the past month, more than 74 million shares remain shorted.

FORBES: Magazine Article

If you want a play on MS, consider Mylan (NYSE: MYL).

FORBES: Investing For A Backlash Against Psychopharmacology

The SOIR for MYL stands at 1.80, as put open interest nearly doubles call open interest among options set to expire in less than three months.

FORBES: Magazine Article

Bristol-Myers Squibb was handed a defeat in a patent lawsuit, which will allow generic drugmaker Mylan Laboratories (nyse: MYL - news - people) to make a lower-cost version of BuSpar, Bristol's fifth best-selling drug.

FORBES: Focus On The Forbes 500s

Among the largest underlying components of VOT, in trading today Amerisourcebergen Corporation ( NYSE: ABC) is down about 0.2%, Consol Energy Incorporated ( NYSE: CNX) is up about 0.1%, and Mylan Incorporated ( NASD: MYL) is lower by about 0.6%.

FORBES: VOT, ABC, CNX, MYL: ETF Outflow Alert

The drug's patent expired months ago, but it was only recently that Genpharm and Mylan (nyse: MYL - news - people ) got their generic versions of the drug passed through the FDA. Roche is counting on Pegasys and Fuzeon, an AIDS drug developed by Trimeris (nasdaq: TRMS - news - people ) to not only maintain sales, but grow them.

FORBES: Magazine Article